Key result
A multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle vaccine protected mice from SARS-CoV-2 challenge after a single immunization and elicited broad neutralizing activity.
Why the study?
Understanding vaccine-elicited protection against SARS-CoV-2 variants and other sarbecoviruses is essential for guiding public health policies.
Does a multivalent sarbecovirus RBD-NP vaccine elicit broadly protective immunity against SARS-CoV-2 variants and other sarbecoviruses in animal models?
Does a multivalent sarbecovirus RBD-NP vaccine elicit broadly protective immunity against SARS-CoV-2 variants and other sarbecoviruses in animal models?
Multivalent sarbecovirus RBD-NPs induce heterotypic protection in animal models, providing proof of principle for broadly protective sarbecovirus vaccines.
No takes yet. Share an insight, caveat, or question.
Supports preclinical development of multivalent RBD-NP vaccines; leaves open human efficacy, dosing, and safety.
Walls et al. (2021) studied SARS-CoV-2 and sarbecovirus infection. Multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle (RBD-NP) vaccine vs. Prefusion-stabilized SARS-CoV-2 spike (HexaPro) was evaluated on Protection against SARS-CoV-2 challenge and serum neutralizing activity. A multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle vaccine protected mice from SARS-CoV-2 challenge after a single immunization and elicited broad neutralizing activity.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: